Effectiveness and safety of methotrexate in the treatment of mycosis fungoides: Real‐world data from a multicentre study
Journal of the European Academy of Dermatology and Venereology · 2025-08 · 39 (8) · 1442-1448
DOI: 10.1111/jdv.20350 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 19.09.2024. Verfasst von Vasiliki Nikolaou und 21 weiteren Autor:innen. Beteiligte Einrichtung: 1st Department of Dermatology, "Andreas Syggros" Hospital for Skin Diseases, National & Kapodistrian University of Athens, Medical School, Athens, Gr…. Hauptthemen laut MEDLINE: Methotrexate, Mycosis Fungoides, Skin Neoplasms, Antimetabolites, Antineoplastic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Methotrexate (MTX) has been a longstanding therapeutic option for mycosis fungoides (MF); however, data on its real‐world effectiveness remain limited.
Objectives
To evaluate treatment‐related outcomes of oral MTX in patients with early‐ and late‐stage MF.
Methods
This is a retrospective multicentre analysis involving MF subjects from five referral centres for cutaneous lymphomas in Greece. Data regarding the effectiveness and safety were analysed.
Results
In total, 211 MF patients were enrolled (males, 68.3%) with a median (IQR) age of diagnosis at 68.3 (56–75) years. Late‐stage (IIB‐IVB) disease was present in 124 patients (59.3%). MTX monotherapy was administered to 112 (53.1%) patients, with 99 receiving combination regimens with phototherapy, interferon and retinoids. MTX was used as first‐line regimen in 103 (48.9%) cases. An overall response rate (ORR) of 55.5% was observed with 29.9% of patients achieving complete responses. MTX demonstrated greater effectiveness as a first‐line treatment compared to subsequent use with no significant differences between monotherapy and combination therapy. The median time to best response was 3.8 months (IQR 2.3–9.9 months). Patients with erythrodermic disease (Stage III) had better ORRs compared to patients with tumour stage disease (Stage II) (61.1% vs. 44.8% respectively). The progression‐free survival (PFS) varied according to stage, with a median PFS of 17.1 months for early‐stage disease, 5.7 months for Stage IIB disease, 46 months for Stage III and 9.6 months for Stage IV disease (0.7‐.). Serious adverse (Grade 3) events leading to treatment discontinuation occurred in 14 (6.7%) cases. All patients received oral MTX once weekly with a median weekly dose of 15 mg/week (7.5–25).
Conclusions
Our findings support MTX as a viable treatment option for MF, particularly when used in the first‐line setting, offering a favourable benefit/risk profile. Response rates are stage‐dependent, with erythrodermic patients achieving superior and durable responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- 1st Department of Dermatology, "Andreas Syggros" Hospital for Skin Diseases, National & Kapodistrian University of Athens, Medical School, Athens, Greece.
- Cutaneous Lymphoma Clinics, 2nd Dermatology Department, Aristotle University School of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece.
- Department of Hematology and Bone Marrow Transplantation, Laikon General Hospital, National & Kapodistrian University of Athens, Medical School, Athens, Greece.
- Department of Dermatology, University General Hospital of Heraklion, Crete, Greece.
- Hemopathology Department, "Evangelismos" General Hospital, Athens, Greece.
- Laboratory of Biological Chemistry, Aristotle Universitiy, School of Medicine, Thessaloniki, Greece.
ORCID-Profile: Vasiliki Nikolaou, Evdoxia Panou, Antonios Tsimpidakis, Ioannis-Alexios Koumprentziotis, Aikaterini Patsatsi, Aliki Velissari, Stella Kaliampou, Aristeidis Vaiopoulos, Evangelia Papadavid
Zitieren
APA
Nikolaou, V., Panou, E., Tsimpidakis, A., Koumprentziotis, I. A., Patsatsi, A., Siakantaris, M., Kruger-Krasagakis, S. E., Marinos, L., Georgiou, E., Lampadaki, K., Velissari, A., Daponte, A. I., Doxastaki, A., Kaliampou, S., Vaiopoulos, A., Konstandinou, I., Koumourtzis, M., Lakiotaki, E., Pappa, V., …, & Papadavid, E. (2025). Effectiveness and safety of methotrexate in the treatment of mycosis fungoides: Real‐world data from a multicentre study. Journal of the European Academy of Dermatology and Venereology, 39(8), 1442-1448. https://doi.org/10.1111/jdv.20350
Vancouver
Nikolaou V, Panou E, Tsimpidakis A, Koumprentziotis IA, Patsatsi A, Siakantaris M, et al. Effectiveness and safety of methotrexate in the treatment of mycosis fungoides: Real‐world data from a multicentre study. Journal of the European Academy of Dermatology and Venereology. 2025;39(8):1442-1448. doi:10.1111/jdv.20350
BibTeX
@article{Nikolaou2025,
author = {Nikolaou, Vasiliki and Panou, Evdoxia and Tsimpidakis, Antonios and Koumprentziotis, Ioannis-Alexios and Patsatsi, Aikaterini and Siakantaris, Marina and Kruger-Krasagakis, Sabine-Elke and Marinos, Leonidas and Georgiou, Elisavet and Lampadaki, Kyriaki and Velissari, Aliki and Daponte, Athina-Ioanna and Doxastaki, Aikaterini and Kaliampou, Stella and Vaiopoulos, Aristeidis and Konstandinou, Iliana and Koumourtzis, Marios and Lakiotaki, Eleftheria and Pappa, Vassiliki and Tsamaldoupis, Athanasios and Stratigos, Alexander and Papadavid, Evangelia},
title = {Effectiveness and safety of methotrexate in the treatment of mycosis fungoides: Real‐world data from a multicentre study},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2025},
volume = {39},
number = {8},
pages = {1442--1448},
doi = {10.1111/jdv.20350}
}
EUVIMED